Literature DB >> 10607763

Primary renal vasculitis in Norfolk--increasing incidence or increasing recognition?

S E Lane1, D G Scott, A Heaton, R A Watts.   

Abstract

BACKGROUND: The incidence of renal vasculitis has previously been estimated using histological definitions or only a single clinical diagnosis, e.g. Wegener's Granulomatosis (WG). Our hospital is the single referral centre for the former Norwich Health Authority (NHA) which encompasses a stable, homogeneous, well-defined and studied population. We estimated the overall incidence of primary renal vasculitis and the incidence within individual clinical disease classifications.
METHODS: All cases of primary renal vasculitis diagnosed within the NHA over 66 months (1992-1997) were identified by review of renal biopsies, the Norfolk Vasculitis Register, hospital discharge summaries and plasmapheresis records. Patients were classified using the 1990 American College of Rheumatology criteria for Polyarteritis Nodosa (PAN), Churg Strauss Syndrome (CSS) and Henoch-Schonlein Purpura; the Chapel Hill Consensus Conference Definitions for Microscopic Polyangiitis (mPA) and the Lanham criteria for CSS. Incidence figures were calculated using the NHA adult population of 413747 (1994). Ninety-five per cent confidence intervals (C.I.) were calculated using the poisson distribution.
RESULTS: The overall annual incidence for primary renal vasculitis was 18/million (C.I. 12.9-24.4). The annual incidence of renal involvement of individual diseases was as follows: WG 7.9/million (95% C.I. 4.7-12.5); mPA 7.5/million (95% C. I. 4.4-12.0); PAN 7.0/million (95% C.I. 4.0-11.4); HSP 3.1/million (95% C.I. 1.2-6.3); CSS 1.3/million (95% C.I. 0.3-3.9).
CONCLUSIONS: The annual incidence for primary renal vasculitis overall and the individual subtypes in Norfolk is much higher than previous European estimates. This may reflect an increasing incidence in primary renal vasculitis with time or underestimation in previous studies. However the incidence of renal vasculitis in our population is markedly lower than reported in Kuwait. There may therefore be true variation in incidence between populations which could have implications for the aetiology of primary vasculitis.

Entities:  

Mesh:

Year:  2000        PMID: 10607763     DOI: 10.1093/ndt/15.1.23

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  [Internists--Update 2006].

Authors:  P Stiefelhagen
Journal:  Internist (Berl)       Date:  2007-02       Impact factor: 0.743

2.  Estimation of BVAS in patients with microscopic polyangiitis in Japan.

Authors:  Mitsuyo Itabashi; Takashi Takei; Taku Morito; Yasuko Yabuki; Hitoe Suzuki; Minoru Ando; Mayuko Akamatsu; Mayuko Yamazaki; Michihiro Mitobe; Yoshihiko Watanabe; Takahiro Mochizuki; Kosaku Nitta
Journal:  Clin Rheumatol       Date:  2011-09-02       Impact factor: 2.980

Review 3.  Microscopic polyangiitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Rheum Dis Clin North Am       Date:  2010-06-11       Impact factor: 2.670

4.  Stable incidence of systemic vasculitides in schleswig-holstein, Germany.

Authors:  Karen Herlyn; Bernhard Hellmich; Wolfgang L Gross; Eva Reinhold-Keller
Journal:  Dtsch Arztebl Int       Date:  2008-05-09       Impact factor: 5.594

5.  Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in chinese patients with clinically suspected vasculitis.

Authors:  Gang Xin; Ming-Hui Zhao; Hai-Yan Wang
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

Review 6.  Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan.

Authors:  Kensuke Joh; Eri Muso; Hidekazu Shigematsu; Masato Nose; Michio Nagata; Yoshihiro Arimura; Wako Yumura; Takashi Wada; Kousaku Nitta; Hirofumi Makino; Yoshio Taguma; Hidetoshi Kaneoka; Yuhsuke Suzuki; Masaki Kobayashi; Akio Koyama; Joichi Usui; Hiroshi Hashimoto; Shoichi Ozaki; Yasuhiko Tomino; Kunihiro Yamagata
Journal:  Clin Exp Nephrol       Date:  2008-04-22       Impact factor: 2.801

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.